A former pharmaceutical executive traded on nonpublic information about an antipsychotic drug’s development, avoiding $1.3 ...

The former vice president of a Carmel Valley pharmaceutical company pleaded guilty Friday to a federal securities fraud count ...

VP at Acadia Pharmaceuticals, pled guilty to insider trading, avoiding a $1.3M loss by illicitly selling shares ahead of a ...

The former CEO of Acadia Pharmaceuticals Inc., headquartered in Sorrento Valley, pleaded guilty Friday to insider trading.

George Demos, former vice president of drug safety and pharmacovigilance at Acadia Pharmaceuticals Inc., is the latest biopharma executive to plead guilty to insider trading charges. BioWorld ...

In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ ... particularly those trading under $20, may find attractive options within the index.

George Demos, 64, formerly of Acadia Pharmaceuticals Inc., admitted selling more than 60,000 company shares just before news broke regarding an issue with one of the company's products ...

Demos, a medical doctor who was the Vice President of Drug Safety and Pharmacovigilance and member of the drug label team at ...

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have earned a consensus rating of “Moderate Buy” from ...

Morgan Stanley assumed coverage of Acadia Pharmaceuticals (ACAD) with an Equal Weight rating and $20 price target The firm sees patent ...

The former vice president of a San Diego-based pharmaceutical company pleaded guilty Friday to a federal securities fraud count for insider trading ... 64, formerly of Acadia Pharmaceuticals ...